Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy

• DOI: 10.1111/dth.13003
• Publication Date: 2019-06-25T19:46:37Z
• Authors: Secil Vural; Mustafa Gündoğdu; Bengu N. Akay; Ayşe Boyvat; Cengizhan Erdem; Pelin Koçyiğit; Seher Bostancı; Hatice Sanli; Nihal Kundakci
• Keywords: Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that causes significant decline in quality of life. There are numerous treatment options; however, real-life data on the efficacy these treatments limited. This study was performed two centers to describe clinical characteristics and assess outcome cohort 139 patients with HS. Data demographic characteristics, Hurley stage comorbidities were collected from patient charts evaluated retrospectively. Treatment response measured HS index (HISCR). Mean body mass 27.8±4.88. Inflammatory present 23%. Among first-line drugs systemic doxycycline resulted 60% HISCR followed by rifampicin-clindamycin combination (46.4%). Isotretinoin had lowest (30.7%) this group. For second-line therapies, all acitretin treated achieved tumor necrosis factor alpha (TNF-α) inhibitors highest HISCR. Currently recommended therapies have moderate Acitretin appears be reasonable alternative for highly effective TNF-α severe resistant Overall, results support excessive play an important role pathogenesis